GeneDx Holdings (WGS) Net Income towards Common Stockholders (2020 - 2026)
GeneDx Holdings (WGS) posted quarterly Net Income towards Common Stockholders of -$63.3 million for Q1 2026, down 869.81% year-over-year from $8.2 million in Q1 2025, and down 258.42% quarter-over-quarter from -$17.7 million in Q4 2025.
GeneDx Holdings (WGS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
GeneDx Holdings (WGS) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$63.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 869.81% year-over-year to -$63.3 million; the TTM figure through Mar 2026 stood at -$77.8 million (down 101.74% YoY), while the FY2025 annual figure was -$21.0 million, up 59.8% from the prior year.
- Net Income towards Common Stockholders eased to -$63.3 million in Q1 2026 per WGS's latest filing, from -$17.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $10.8 million in Q2 2025 and bottomed at -$308.7 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$50.7 million across 5 years, with a median of -$29.2 million in 2024.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders soared 137.06% — and 2026, when it tumbled 869.81%.
- GeneDx Holdings' Net Income towards Common Stockholders stood at -$308.7 million in 2022, then soared by 91.66% to -$25.8 million in 2023, then jumped by 121.19% to $5.5 million in 2024, then tumbled by 423.73% to -$17.7 million in 2025, then sank by 258.42% to -$63.3 million in 2026.
- Business Quant data shows WGS's Net Income towards Common Stockholders at -$63.3 million in Q1 2026, -$17.7 million in Q4 2025, and -$7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 338.41 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -85.11 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 324.00 Mn |
| 10 | GeneDx Holdings | 2.08 Bn | 1.94 Bn | 78.24 Mn | -17.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.74 Mn |
| Mar 31, 2026 | -63.32 Mn |
| Dec 31, 2025 | -17.67 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | 10.81 Mn |
| Mar 31, 2025 | -6.53 Mn |
| Dec 31, 2024 | 5.46 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | -29.16 Mn |
| Mar 31, 2024 | -20.24 Mn |
| Dec 31, 2023 | -25.76 Mn |
| Sep 30, 2023 | -42.29 Mn |
| Jun 30, 2023 | -46.72 Mn |
| Mar 31, 2023 | -60.99 Mn |
| Dec 31, 2022 | -308.72 Mn |
| Sep 30, 2022 | -77.58 Mn |
| Jun 30, 2022 | -85.74 Mn |
| Mar 31, 2022 | -76.90 Mn |
| Dec 31, 2021 | -40.19 Mn |
| Sep 30, 2021 | 32.73 Mn |